No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Visionairy Health Secures CE Marking for its AI-Based X-Ray Triage Tool

Editor: What To Know

  • “We’re excited to receive CE Marking, as this allows us to deploy X1 in Europe and delve into the other markets in the Middle East, Africa, and Asia as a next step,”.
  • X1 is a state-of-the-art medical device that uses deep learning to analyze chest x-rays, flagging those images that are suggestive of the presence of one or more of 15 pre-specified findings (including tuberculosis, pneumothorax, and lung nodules).
  • X1 is part of a suite of AI products being developed by VH to help clinicians manage the ever-increasing volume of diagnostic radiography in hospitals and clinics around the world.

Visionairy Health, is a Health-tech AI company. Today they announced they obtained CE Marking for X1, its artificial intelligence (AI) based chest x-ray triage and prioritization product. X1 is a state-of-the-art medical device that uses deep learning to analyze chest x-rays, flagging those images that are suggestive of the presence of one or more of 15 pre-specified findings (including tuberculosis, pneumothorax, and lung nodules).

Visionairy Health notes it has been trained using hundreds of thousands of chest x-rays from dozens of geographical locations. X1 is PACS agnostic and can be easily integrated with existing radiology software. The software’s notifications act as a secondary check in parallel to physicians’ independent assessment to ensure that imaging studies with any prespecified findings are brought to their immediate attention.

“We’re excited to receive CE Marking, as this allows us to deploy X1 in Europe and delve into the other markets in the Middle East, Africa, and Asia as a next step,” says Moustafa Amin, Co-founder and CEO of Visionairy Health.

Visionairy Health has partnerships with large healthcare providers in those regions and they are eager to use X1. Dr. Hesham Zaki, VP of Radiology and Informatics at GNP Hospitals Group, an early partner of VH, says: “At GNP, we process a large number of chest x-rays every day, so we are looking forward to using the X1 triage tool. With X1, our physicians can be more efficient and focus on scans that require their immediate attention.”

X1 is part of a suite of AI products being developed by VH to help clinicians manage the ever-increasing volume of diagnostic radiography in hospitals and clinics around the world. The CE marking of X1 paves the way for its commercial launch in most regions of the world

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy